Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Human HER2 ELISA Kit for Sandwich ELISA - ABIN625296
Laidi, Bouziane, Lakhdar, Khabouze, Rhrab, Zaoui: Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status. in OncoTargets and therapy 2014
Human HER2 ELISA Kit for Sandwich ELISA - ABIN921095
Tao, Suhua, Juanjuan, Zongzhi, Juan, Dandan: In vitro study on human cytomegalovirus affecting early pregnancy villous EVT's invasion function. in Virology journal 2011
Vinorelbine/gemcitabine appeared to be a more valuable first-line treatment regimen than vinorelbine/cisplatin in anthracycline- and taxane-pretreated patients with HER2-negative advanced breast cancer.
This study reports the novel findings that HER2 increases PARP1 (show PARP1 ELISA Kits) protein via suppression of the let-7a miRNA, which regulates the PARP1 (show PARP1 ELISA Kits) 3'-UTR (show UTS2R ELISA Kits). Moreover, HER2 status correlates with high PARP1 (show PARP1 ELISA Kits) and low let-7a in breast cancer clinical specimens.
Both ERBB2 and ERBB3 (show ERBB3 ELISA Kits) are essential for normal proliferation of skin keratinocytes, but in contrast to ERBB3 (show ERBB3 ELISA Kits), ERBB2 is essential for migration of human keratinocytes.
Study showed that 25 % of patients with bladder transitional cell carcinoma has Her2/neu over-expression. This Her2/neu (over-expression/amplification) status was significantly associated with disease aggressiveness and poor outcome.
Relapse-free survival (RFS) was significantly shorter in patients who were double positive for EGFR (show EGFR ELISA Kits) and HER2. Our results suggest that EGFR (show EGFR ELISA Kits) and HER2 are potential therapeutic targets and that their co-expression is a prognostic factor for cervical adenocarcinoma.
ERBB2 methylation status in myocardial tissue contributes to a fraction of the variability in cardiac ERBB2 expression. This study provides a foundation to test whether differential DNA methylation (show HELLS ELISA Kits) status in the proximal promoter region of ERBB2 impacts on the cardiotoxic potential of trastuzumab by modifying the intracellular dynamics of ERBB2.
There is a small, distinct category of HER2-positive CRC (show CALR ELISA Kits) patients who are candidates for HER2-targeted therapy. CGS has the same sensitivity as IHC and FISH for detecting HER2-positive patients.
An interdisciplinary German expert group took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication from the perspective of pathologists and therapists.
Very low density (VLD) and HER2 positivity were prognostically significant factors independent of the NPI (show NPX1 ELISA Kits). Furthermore, the incorporation of VLD and HER2 to the NPI (show NPX1 ELISA Kits) served to enhance its accuracy, thus offering a readily available and more accurate method for the evaluation of patient prognosis.
results from this study demonstrate that MUC13 (show MUC13 ELISA Kits) functionally interacts and activates HER2 at p1248 in PDAC cells, leading to stimulation of HER2 signaling cascade, including ERK1/2 (show MAPK1/3 ELISA Kits), FAK (show PTK2 ELISA Kits), AKT (show AKT1 ELISA Kits) and PAK1 (show PAK1 ELISA Kits) as well as regulation of the growth, cytoskeleton remodeling and motility, invasion of PDAC cells-all collectively contributing to PDAC progression.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB (show NUMB ELISA Kits) and NUMBL (show NUMBL ELISA Kits) interacted with small GTPase (show RACGAP1 ELISA Kits) Rab7 (show RAB7A ELISA Kits) to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta (show TGFB1 ELISA Kits), EGFR (show EGFR ELISA Kits) and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR (show EGFR ELISA Kits)-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB (show EGFR ELISA Kits) receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS (show IARS ELISA Kits) pathway in mouse breast cancer model.
It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis
Study showed that suppression of STAT3 (show STAT3 ELISA Kits), STAT5 (show STAT5A ELISA Kits), and STAT6 (show STAT6 ELISA Kits) and overexpression of the proapoptotic factor STAT1 (show STAT1 ELISA Kits), which provides p53 (show TP53 ELISA Kits)-mediated apoptosis, are the causes for increasing the number of apoptotic neurons in physiological aging. HER-2 tyrosine kinase receptor (show KDR ELISA Kits) overexpression promotes neuronal survival through activation of STAT (show STAT1 ELISA Kits)-signaling pathway with simultaneous suppression of the proapoptotic factor STAT1 (show STAT1 ELISA Kits)
that myocardial ErbB2 and beta-adrenergic receptors signalling are linked in a feedback loop with beta-adrenergic receptors activation leading to increased ErbB2 expression and activity
Metformin inhibits breast tumor angiogenesis and suggest role of HIF-1alpha (show HIF1A ELISA Kits)-VEGF (show VEGFA ELISA Kits) signaling axis in mediating HER2-induced tumor angiogenesis.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
receptor tyrosine-protein kinase erbB-2
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, proto-oncogene NEU
, proto-oncogene c-ErbB-2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, tyrosine kinase-type cell surface receptor HER2
, Neu oncogene
, avian erythroblastosis oncogene B 2